JP2024510274A5 - - Google Patents

Info

Publication number
JP2024510274A5
JP2024510274A5 JP2023557092A JP2023557092A JP2024510274A5 JP 2024510274 A5 JP2024510274 A5 JP 2024510274A5 JP 2023557092 A JP2023557092 A JP 2023557092A JP 2023557092 A JP2023557092 A JP 2023557092A JP 2024510274 A5 JP2024510274 A5 JP 2024510274A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
optionally substituted
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/106028 external-priority patent/WO2022193499A1/en
Publication of JP2024510274A publication Critical patent/JP2024510274A/ja
Publication of JP2024510274A5 publication Critical patent/JP2024510274A5/ja
Pending legal-status Critical Current

Links

JP2023557092A 2021-03-16 2021-07-13 アミノヘテロアリール化合物および組成物 Pending JP2024510274A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/081177 2021-03-16
CN2021081177 2021-03-16
PCT/CN2021/106028 WO2022193499A1 (en) 2021-03-16 2021-07-13 Amino heteroaryl compounds and compositions

Publications (2)

Publication Number Publication Date
JP2024510274A JP2024510274A (ja) 2024-03-06
JP2024510274A5 true JP2024510274A5 (cg-RX-API-DMAC7.html) 2024-07-23

Family

ID=83321944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557092A Pending JP2024510274A (ja) 2021-03-16 2021-07-13 アミノヘテロアリール化合物および組成物

Country Status (6)

Country Link
US (1) US20240246944A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308556A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024510274A (cg-RX-API-DMAC7.html)
CN (1) CN117083268B (cg-RX-API-DMAC7.html)
CA (1) CA3213816A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022193499A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122520625A (zh) 2020-12-22 2026-08-07 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
TWI925948B (zh) * 2021-02-06 2026-05-21 大陸商正大天晴藥業集團股份有限公司 含聯環的tyk2抑制劑化合物、藥物組合物及其用途
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
CN117263913A (zh) 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
WO2024044486A1 (en) * 2022-08-22 2024-02-29 Ajax Therapeutics, Inc. Jak2 inhibitor compounds
US20260098017A1 (en) * 2022-12-24 2026-04-09 Tianjin Pharmaceutical Biotechnology Co., Ltd. Novel aromatic ring derivative containing amide substitution and use thereof
WO2024174229A1 (en) * 2023-02-24 2024-08-29 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Covalent binding compounds and compositions
CN116162093B (zh) * 2023-04-25 2023-06-23 中南大学湘雅医院 一种tyk2抑制剂化合物及其用途
CN117624126B (zh) * 2023-12-05 2026-01-30 中国药科大学 选择性酪氨酸激酶2(tyk2)抑制剂化合物、合成方法及用途
WO2025186427A1 (en) 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
WO2025255092A1 (en) * 2024-06-03 2025-12-11 Artax Biopharma Inc. Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
KR102782807B1 (ko) 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
US10836770B2 (en) 2016-10-07 2020-11-17 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
TWI763722B (zh) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
MA48602A (fr) 2016-12-13 2020-03-18 Bristol Myers Squibb Co Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
MY202167A (en) 2017-11-21 2024-04-12 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
JP7485609B2 (ja) 2018-03-22 2024-05-16 ブリストル-マイヤーズ スクイブ カンパニー IL-12、IL-23および/またはIFNα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
EP3849981B1 (en) 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Tyk2阻害剤およびその使用
RS66346B1 (sr) * 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
KR102858043B1 (ko) * 2018-10-30 2025-09-10 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
WO2020112937A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
KR102943760B1 (ko) 2019-01-28 2026-03-26 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
WO2020159904A1 (en) * 2019-01-30 2020-08-06 Bristol-Myers Squibb Company Amide-disubstituted pyridine or pyridazine compounds
CN111909140A (zh) 2019-04-12 2020-11-10 明慧医药(杭州)有限公司 作为tyk2抑制剂的杂环化合物及合成和使用方法
KR20230004771A (ko) * 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물

Similar Documents

Publication Publication Date Title
RU2014110623A (ru) Пирролопиразиновые ингибиторы киназы
JP2025508192A5 (cg-RX-API-DMAC7.html)
JP2019530699A5 (cg-RX-API-DMAC7.html)
JP2020537657A5 (cg-RX-API-DMAC7.html)
JP2017506675A5 (cg-RX-API-DMAC7.html)
JP2021098751A (ja) Jakキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物
JP2013530236A5 (cg-RX-API-DMAC7.html)
JP2015502387A5 (cg-RX-API-DMAC7.html)
JP2023520916A5 (cg-RX-API-DMAC7.html)
JP2022550640A5 (cg-RX-API-DMAC7.html)
JP2018537483A (ja) ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法
JP2013533883A5 (cg-RX-API-DMAC7.html)
JP2013530238A5 (cg-RX-API-DMAC7.html)
JP7101685B2 (ja) 新規jakキナーゼ阻害剤としての二環式アミン
ME02754B (me) Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
US20150290190A1 (en) [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS P2X7 MODULATORS
JP2020511438A5 (cg-RX-API-DMAC7.html)
JP2013519704A5 (cg-RX-API-DMAC7.html)
US20230183188A1 (en) Enpp1 modulators and uses thereof
JP2023533003A5 (cg-RX-API-DMAC7.html)
JP2023528421A5 (cg-RX-API-DMAC7.html)
JP2022550641A5 (cg-RX-API-DMAC7.html)
JP2019501927A5 (cg-RX-API-DMAC7.html)
CN103298807A (zh) 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
JP2024502473A5 (cg-RX-API-DMAC7.html)